AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes
September 16, 2015 07:30 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - September 16, 2015) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies,...
AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
June 29, 2015 08:00 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - June 29, 2015) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies,...
AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
June 08, 2015 07:30 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - June 08, 2015) - AB101 drug substance retained similar receptor binding affinity and receptor-mediated biological activity compared to native insulinSingle dose...
AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
May 11, 2015 08:00 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - May 11, 2015) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced...
AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
January 08, 2015 07:35 ET
|
AntriaBio, Inc.
LOUISVILLE, CO and MENLO PARK, CA--(Marketwired - Jan 8, 2015) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended...
AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species
January 07, 2015 08:00 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - Jan 7, 2015) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies,...
AntriaBio Announces $7 Million Private Placement
January 05, 2015 07:35 ET
|
AntriaBio Inc.
LOUISVILLE, CO--(Marketwired - Jan 5, 2015) - AntriaBio, Inc. ("Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that...
AntriaBio Extinguishes $44 Million Contingent Liability
November 10, 2014 08:05 ET
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - Nov 10, 2014) - AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has...
AntriaBio Appoints C. Ronald Kahn, M.D. to Its Scientific Advisory Board
June 23, 2014 07:35 ET
|
AntriaBio Inc.
MENLO PARK, CA--(Marketwired - Jun 23, 2014) - AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic...
AntriaBio, Inc. to Present at the Third Annual Marcum MicroCap Conference on Thursday, May 29, 2014
May 22, 2014 07:35 ET
|
AntriaBio
MENLO PARK, CA--(Marketwired - May 22, 2014) - AntriaBio, Inc. (OTCQB: ANTB) a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic...